Ameritas Advisory Services LLC Has $1.08 Million Stock Position in Novo Nordisk A/S $NVO

Ameritas Advisory Services LLC increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 289.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,382 shares of the company’s stock after acquiring an additional 14,405 shares during the quarter. Ameritas Advisory Services LLC’s holdings in Novo Nordisk A/S were worth $1,075,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. True Wealth Design LLC raised its holdings in Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after acquiring an additional 300 shares in the last quarter. NewSquare Capital LLC increased its position in shares of Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after purchasing an additional 282 shares during the period. Guerra Advisors Inc bought a new position in Novo Nordisk A/S in the third quarter worth $25,000. Strengthening Families & Communities LLC acquired a new stake in Novo Nordisk A/S during the third quarter worth $30,000. Finally, Mid American Wealth Advisory Group Inc. bought a new stake in Novo Nordisk A/S in the 2nd quarter valued at $37,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday. CICC Research began coverage on Novo Nordisk A/S in a report on Friday, January 9th. They set an “outperform” rating and a $73.50 price objective for the company. Zacks Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, February 9th. Finally, Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Seven investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Hold” and a consensus target price of $56.07.

Novo Nordisk A/S Stock Up 1.4%

Novo Nordisk A/S stock opened at $49.59 on Friday. The company has a 50 day moving average of $53.74 and a 200-day moving average of $53.22. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $93.80. The stock has a market capitalization of $221.43 billion, a PE ratio of 14.29 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a $1.2751 dividend. The ex-dividend date is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is currently 23.63%.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Berenberg maintained its Buy rating on Novo Nordisk, reinforcing investor confidence in the company’s growth outlook and valuation support from a respected European bank. Berenberg Bank Sticks to Their Buy Rating for Novo Nordisk (NVO)
• Positive Sentiment: IQVIA data show Wegovy oral-pill prescriptions hitting ~38,220 in week five post-launch, signaling strong early uptake for the new oral formulation and supporting near-term revenue momentum. Novo’s Wegovy pill tracks over 38,000 prescriptions in fifth week
• Positive Sentiment: Company update: Novo completed a Phase 3 study of oral semaglutide in youth diabetes care — a potential label expansion that could broaden the drug’s addressable market if approved. Novo Nordisk Advances Oral Semaglutide Into Youth Diabetes Care
• Positive Sentiment: Legal/market protection: U.S. officials may act against Hims after its attempted sale of a compounded Wegovy copy, which could help defend Novo’s IP and commercial position. US could take action including fines against Hims after brief Wegovy copy launch
• Positive Sentiment: Product strategy: Novo plans to introduce Wegovy in vial presentations (and other device formats), a move to improve access, pricing flexibility and supply resiliency amid competition. Novo Nordisk plans Wegovy vials amid obesity-drug competition
• Positive Sentiment: Usage trend: A study finds many Wegovy pill users are new to GLP‑1s, suggesting the product is bringing first‑time patients into the class and expanding market demand. Many users of Novo Nordisk Wegovy pill new to GLP-1s – study
• Neutral Sentiment: Company expansion: Coverage on Novo’s broader global healthcare initiatives highlights long‑term growth avenues but is less likely to move near‑term sentiment. How Is Novo Nordisk (NYSE:NVO) Expanding Its Global Healthcare Reach?
• Neutral Sentiment: Industry context: A CNBC piece on pharma’s “reset” around pricing and pipelines frames regulatory and pricing headwinds that apply across the sector. Prices, pipelines and patent cliffs: Inside pharma’s big reset
• Neutral Sentiment: Competitive landscape: Analysis comparing Eli Lilly and Novo Nordisk underscores intense competition in a rapidly growing weight‑loss market; investors should watch share trends and margin pressure. Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market
• Negative Sentiment: Regulatory/legal risk: Coverage about FDA warnings and potential lawsuits tied to Wegovy highlights an ongoing downside risk to valuation if safety signals or litigation escalate. FDA Wegovy Warning And Lawsuits Test Novo Nordisk Valuation Story

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.